Key result
Lepodisiran emerges as a novel siRNA targeting Lp(a) for ASCVD risk reduction.
Why the study?
Does lepodisiran reduce lipoprotein (a) and major cardiovascular events in patients with established ASCVD or at high cardiovascular risk?
Does lepodisiran reduce lipoprotein (a) and major cardiovascular events in patients with established ASCVD or at high cardiovascular risk?
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Lepodisiran is an emerging siRNA therapy targeting lipoprotein (a) that is currently under investigation in Phase 3 trials for cardiovascular risk reduction.
An elevated lipoprotein (a) concentration has been established as an independent risk factor for atherosclerotic cardiovascular disease (ASCVD). There is a high prevalence of elevated lipoprotein (a) in the general population, and given the significant burden of ASCVD, researchers have developed novel therapeutic drugs with a direct lipoprotein (a) reducing effect that are currently under investigation. One of these medications is lepodisiran, a small interfering RNA targeting lipoprotein (a). This drug has undergone safety assessment (in Phase 1 and 2 randomized control trials [RCTs]) as well as efficacy assessment (Phase 2 RCT, ALPACA Trial). A phase 3 RCT, ACCLAIM-Lp(a), is currently ongoing with the main purpose of assessing the effect on major cardiovascular events in patients with established ASCVD or at high cardiovascular risk. Herein, we present an updated review on this lipoprotein (a) lowering agent, including the results of the published clinical trials and the design of the ongoing phase 3 clinical trial.
Urina-Jassir et al. (2026) conducted a review in Elevated lipoprotein (a) and atherosclerotic cardiovascular disease. Lepodisiran was evaluated. Lepodisiran is a novel small interfering RNA targeting lipoprotein (a) that is currently undergoing clinical evaluation for cardiovascular risk reduction in patients with or at high risk of ASCVD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: